Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

BAFF: A Fulcrum Between Resistance to Infection & Autoimmunity

Lara C. Pullen, PhD  |  May 31, 2017

“Overall, the evolutionary scenario we propose is that BAFF-var was selected as an adaptive response to malaria infection, resulting in an increased present-day risk of autoimmunity,” they conclude.

If true, it would be another example of a mutation that provides advantages to the fitness of mutants, while at the same time leading to disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Steri M, Orrù V, Idda ML, et al. Overexpression of the cytokine BAFF and autoimmunity risk. N Engl J Med. 2017 Apr 27;376(17):1615–1626. doi: 10.1056/NEJMoa1610528.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:autoimmunityB cell activating factor (BAFF)B cellsSLEsystemic lupus erythematosus (SLE)

Related Articles

    Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease

    January 1, 2010

    A perspective on B cell–targeted therapies in autoimmune disease

    T Cells in Systemic Lupus Erythematosus

    August 1, 2011

    Progress toward targeted therapy

    Common Variable Immunodeficiency

    June 1, 2008

    Genetic insights into a complex and baffling disease

    A&R Abstracts – T CELLS

    August 1, 2011

    For Further Reading

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences